Lung Cancer News
Results from 2 other cohorts of this phase 2 study demonstrated that genotype-directed therapy with dabrafenib plus trametinib was effective in previously treated patients with BRAFV600E-mutant NSCLC.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
For this randomized phase 3 study, patients were assigned to motesanib plus paclitaxel and carboplatin (197 patients) or to placebo plus paclitaxel and carboplatin (204 patients).
Researchers randomly assigned 87 patients with unresectable, non-sarcomatoid MPM to receive 6 cycles of standard pemetrexed and cisplatin with nintedanib 200 mg twice daily or placebo, followed by nintedanib or placebo monotherapy.
Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.
Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.
Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).
The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.
Although guidelines advocate follow-ups consisting of clinic visits and CT-scans, there is a lack of robust data supporting these recommendations.
Adoptive cellular immunotherapy has not been widely used for cancer treatment.
Previously collected data from the AURA study demonstrated that osimertinib may be effective as first-line therapy for this patient population.
In a secondary analysis of the CANTOS trial, researchers analyzed the effect canakinumab's inhibition of interleukin-1β may have on the risk of cancer.
A previous analysis demonstrated that everolimus prolonged progression-free survival — the primary endpoint of the study — compared with placebo.
Increased vitamin B intake is hypothesized to interfere with the one-carbon metabolism pathway, a process that is thought to be important for gene expression regulation and DNA integrity maintenance, thereby increasing carcinogenic risk.
Atezolizumab monotherapy has a good overall response rate (ORR) and favorable safety profile in patients with advanced PD-L1 expressing non-small cell lung cancer (NSCLC).
Compared with ALK¬-positive patients, participants with ROS1 rearrangements were less likely to present with extrathoracic and brain metastases.
One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).
Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.
The FDA granted priority review to alectinib for the treatment of patients with ALK-positive, locally advanced or metastatic NSCLC.
The FDA granted breakthrough therapy designation to durvalumab for patients with locally advanced, unresectable NSCLC who do not relapse after platinum-based chemoradiation.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- beta-Carotene and Cancer
- Novel Therapeutic Target in Chronic Lymphocytic Leukemia Cells Identified
- Venetoclax Plus Rituximab May Prolong Progression-free Survival in CLL
- Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer
- Different Types of Obesity May Increase Risk of Breast Cancer Subtypes